Rabeprazole Sodium is a proton pump inhibitor (PPI) to reduce stomach acid and is used for the treatment of gastroesophageal reflux disease (GERD), duodenal ulcers, and used in combination with antibiotics to treat Helicobacter pylori bacterial infections in the stomach.

The global Rabeprazole Sodium market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Rabeprazole Sodium volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rabeprazole Sodium market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Rabeprazole Sodium in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Rabeprazole Sodium manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
JSN Chemicals
Jubilant Pharma
Smaart Pharmaceutticals
Shanghai Pharma Group Changzhou Kony Pharmaceutical
ASN Corporation
Intas
Sterile India
Zhejiang Yongtai Technology
Enal Drugs Private Limited
Syntech Chem＆Pharm

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Rabeprazole Sodium Monohydrate
Rabeprazole Sodium Crystalline

Segment by Application
Gastroesophageal Reflux Disease Treatment
Duodenal Ulcer Treatment
Others